Heterozygous familial hypercholesterolemia (heFH) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Heterozygous familial hypercholesterolemia (heFH) – Pipeline Review, H2 2016’, provides an overview of the Heterozygous familial hypercholesterolemia (heFH) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Heterozygous familial hypercholesterolemia (heFH), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Heterozygous familial hypercholesterolemia (heFH) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Heterozygous familial hypercholesterolemia (heFH)

The report reviews pipeline therapeutics for Heterozygous familial hypercholesterolemia (heFH) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Heterozygous familial hypercholesterolemia (heFH) therapeutics and enlists all their major and minor projects

The report assesses Heterozygous familial hypercholesterolemia (heFH) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Heterozygous familial hypercholesterolemia (heFH)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Heterozygous familial hypercholesterolemia (heFH)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Heterozygous familial hypercholesterolemia (heFH) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Gemphire Therapeutics Inc

Merck & Co Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Heterozygous familial hypercholesterolemia (heFH) Overview 6

Therapeutics Development 7

Pipeline Products for Heterozygous familial hypercholesterolemia (heFH) - Overview 7

Heterozygous familial hypercholesterolemia (heFH) - Therapeutics under Development by Companies 8

Heterozygous familial hypercholesterolemia (heFH) - Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Early Stage Products 11

Heterozygous familial hypercholesterolemia (heFH) - Products under Development by Companies 12

Heterozygous familial hypercholesterolemia (heFH) - Companies Involved in Therapeutics Development 13

Gemphire Therapeutics Inc 13

Merck & Co Inc 14

Heterozygous familial hypercholesterolemia (heFH) - Therapeutics Assessment 15

Assessment by Monotherapy Products 15

Assessment by Combination Products 16

Assessment by Target 17

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 22

Drug Profiles 23

(atorvastatin calcium + ezetimibe) - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

anacetrapib - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

gemcabene calcium - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

MGL-3196 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

MGL-3745 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Heterozygous familial hypercholesterolemia (heFH) - Dormant Projects 31

Heterozygous familial hypercholesterolemia (heFH) - Discontinued Products 32

Heterozygous familial hypercholesterolemia (heFH) - Product Development Milestones 33

Featured News & Press Releases 33

Nov 28, 2016: Gemphire Therapeutics Enrolls First Patients in the ROYAL-1 Trial Investigating Gemcabene in Hypercholesterolemia 33

Jan 14, 2014: Merck Voluntarily Recalls All Lots of LIPTRUZET in the United States From Wholesalers Due to Packaging Defects 33

Appendix 35

Methodology 35

Coverage 35

Secondary Research 35

Primary Research 35

Expert Panel Validation 35

Contact Us 35

Disclaimer 36

List of Tables

List of Tables

Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Early Stage Development, H2 2016 11

Products under Development by Companies, H2 2016 12

Heterozygous familial hypercholesterolemia (heFH) – Pipeline by Gemphire Therapeutics Inc, H2 2016 13

Heterozygous familial hypercholesterolemia (heFH) – Pipeline by Merck & Co Inc, H2 2016 14

Assessment by Monotherapy Products, H2 2016 15

Assessment by Combination Products, H2 2016 16

Number of Products by Stage and Target, H2 2016 18

Number of Products by Stage and Mechanism of Action, H2 2016 20

Number of Products by Stage and Route of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 22

Heterozygous familial hypercholesterolemia (heFH) – Dormant Projects, H2 2016 31

Heterozygous familial hypercholesterolemia (heFH) – Discontinued Products, H2 2016 32

List of Figures

List of Figures

Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 10

Assessment by Monotherapy Products, H2 2016 15

Number of Products by Targets, H2 2016 17

Number of Products by Stage and Targets, H2 2016 17

Number of Products by Mechanism of Actions, H2 2016 19

Number of Products by Stage and Mechanism of Actions, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 21

Number of Products by Stage and Molecule Types, H2 2016 22

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports